Session III: September 20, 2023

Enhancing Clinical Trial Awareness and Increasing Participation of Black Patients

Successful prostate cancer clinical trials have ushered in a new generation of treatment therapies. However, the lack of participation in these trials by Black patients is a significant missed opportunity. This session highlighted some of the missed opportunities and presented strategies by trial sponsors to diversify their trials. The session also included patients’ testimonials about their clinical trial experiences and needs. PHEN’s Clinical Trials rally showcases PHEN’s efforts to increase clinical trial awareness and participation by Black patients.

Session III Program

Watch Video     Welcome and Opening Remarks: Mr. Thomas Farrington, President and Founder, PHEN

Watch Video     Moderator: Keith Crawford, MD, PhD, Director of Clinical Trials and Patient Education, PHEN

Watch Video     Clinical Trial Successes and Missed Opportunities: Richard Lee, MD, PhD, Clinical Co-Director, The Claire and John Bertucci Center for Genitourinary Cancers, Mass General Cancer Center

Watch Video     Strategies to Diversify Patients’ Participation in Clinical Trials

      • Pfizer: Ms. Sandra Amaro, MBA, Head of Clinical Trial Diversity
      • Merck: Ms. Cameron Davis, Associate Director, Clinical Trial Diversity
      • Novartis: Ms. Kim Fookes, Global Head, Diversity and Inclusion in Clinical Trials, Global Development
      • Janssen: Ms. Lisa Lewis, Director, Diversity, Equity & Inclusion in Clinical Trials – Oncology
      • Prostate Cancer Clinical Trials Consortium: Ms. Natalie Macario, Promise Project Associate
      • Macrogenics: Ms. Amy Worth, Associate Director in Clinical Operations

Watch Video     Prostate Cancer Patients’ Clinical Trials Experiences

Watch Video     Closing Remarks: Mr. Thomas Farrington

Session 3 Survey Results


PHEN thanks its sponsors for their support of the 2024 Summit.